107 related articles for article (PubMed ID: 37149486)
1. Facility type is associated with improved perioperative and oncologic outcomes after minimally invasive surgery for pancreatic cancer.
Servin-Rojas M; Shafique N; Sell NM; Gamblin TC; Qadan M
HPB (Oxford); 2023 Aug; 25(8):933-940. PubMed ID: 37149486
[TBL] [Abstract][Full Text] [Related]
2. Improved oncologic outcomes for minimally invasive left pancreatectomy: Propensity-score matched analysis of the National Cancer Database.
Watson MD; Baimas-George MR; Thompson KJ; Iannitti DA; Ocuin LM; Baker EH; Martinie JB; Vrochides D
J Surg Oncol; 2020 Dec; 122(7):1383-1392. PubMed ID: 32772366
[TBL] [Abstract][Full Text] [Related]
3. Perioperative and oncological outcomes following minimally invasive versus open pancreaticoduodenectomy for pancreatic duct adenocarcinoma.
Sun R; Yu J; Zhang Y; Liang Z; Han X
Surg Endosc; 2021 May; 35(5):2273-2285. PubMed ID: 32632485
[TBL] [Abstract][Full Text] [Related]
4. Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodenectomy.
Hue JJ; Sugumar K; Markt SC; Hardacre JM; Ammori JB; Rothermel LD; Winter JM; Ocuin LM
Surgery; 2021 Jul; 170(1):207-214. PubMed ID: 33454134
[TBL] [Abstract][Full Text] [Related]
5. Regional trends of minimally invasive radical hysterectomy for cervical cancer and exploration of perioperative outcomes.
Holtzman S; Chaoul J; Finkelstein M; Kolev V; Zakashansky K
Cancer Epidemiol; 2022 Apr; 77():102095. PubMed ID: 35078009
[TBL] [Abstract][Full Text] [Related]
6. Patterns of Adjuvant Chemotherapy Use and Association With Survival in Adults 80 Years and Older With Pancreatic Adenocarcinoma.
Mehtsun WT; McCleary NJ; Maduekwe UN; Wolpin BM; Schrag D; Wang J
JAMA Oncol; 2022 Jan; 8(1):88-95. PubMed ID: 34854874
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study.
Janssen QP; van Dam JL; Prakash LR; Doppenberg D; Crane CH; van Eijck CHJ; Ellsworth SG; Jarnagin WR; O'Reilly EM; Paniccia A; Reyngold M; Besselink MG; Katz MHG; Tzeng CD; Zureikat AH; Groot Koerkamp B; Wei AC;
J Natl Compr Canc Netw; 2022 Jul; 20(7):783-791.e1. PubMed ID: 35830887
[TBL] [Abstract][Full Text] [Related]
8. Assessment of textbook oncologic outcomes following pancreaticoduodenectomy for pancreatic adenocarcinoma.
Sweigert PJ; Eguia E; Baker MS; Paredes AZ; Tsilimigras DI; Dillhoff M; Ejaz A; Cloyd J; Tsung A; Pawlik TM
J Surg Oncol; 2020 May; 121(6):936-944. PubMed ID: 32124437
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of minimally invasive and open distal pancreatectomy for ductal adenocarcinoma.
Magge D; Gooding W; Choudry H; Steve J; Steel J; Zureikat A; Krasinskas A; Daouadi M; Lee KK; Hughes SJ; Zeh HJ; Moser AJ
JAMA Surg; 2013 Jun; 148(6):525-31. PubMed ID: 23426503
[TBL] [Abstract][Full Text] [Related]
10. Is early-stage pancreatic adenocarcinoma truly early: stage migration on final pathology with surgery-first versus neoadjuvant therapy sequencing.
Lee AJ; Simoneau E; Chiang YJ; Lee JE; Kim MP; Aloia TA; Vauthey JN; Katz MH; Tzeng CD
HPB (Oxford); 2019 Sep; 21(9):1203-1210. PubMed ID: 30799277
[TBL] [Abstract][Full Text] [Related]
11. Minimally Invasive versus Open Distal Pancreatectomy for Ductal Adenocarcinoma (DIPLOMA): A Pan-European Propensity Score Matched Study.
van Hilst J; de Rooij T; Klompmaker S; Rawashdeh M; Aleotti F; Al-Sarireh B; Alseidi A; Ateeb Z; Balzano G; Berrevoet F; Björnsson B; Boggi U; Busch OR; Butturini G; Casadei R; Del Chiaro M; Chikhladze S; Cipriani F; van Dam R; Damoli I; van Dieren S; Dokmak S; Edwin B; van Eijck C; Fabre JM; Falconi M; Farges O; Fernández-Cruz L; Forgione A; Frigerio I; Fuks D; Gavazzi F; Gayet B; Giardino A; Groot Koerkamp B; Hackert T; Hassenpflug M; Kabir I; Keck T; Khatkov I; Kusar M; Lombardo C; Marchegiani G; Marshall R; Menon KV; Montorsi M; Orville M; de Pastena M; Pietrabissa A; Poves I; Primrose J; Pugliese R; Ricci C; Roberts K; Røsok B; Sahakyan MA; Sánchez-Cabús S; Sandström P; Scovel L; Solaini L; Soonawalla Z; Souche FR; Sutcliffe RP; Tiberio GA; Tomazic A; Troisi R; Wellner U; White S; Wittel UA; Zerbi A; Bassi C; Besselink MG; Abu Hilal M;
Ann Surg; 2019 Jan; 269(1):10-17. PubMed ID: 29099399
[TBL] [Abstract][Full Text] [Related]
12. Disparities in Pancreatic Ductal Adenocarcinoma-The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes.
Riner AN; Underwood PW; Yang K; Herremans KM; Cameron ME; Chamala S; Qiu P; George TJ; Permuth JB; Merchant NB; Trevino JG
Cancer Med; 2020 Jun; 9(12):4069-4082. PubMed ID: 32285629
[TBL] [Abstract][Full Text] [Related]
13. [Chinese expert consensus on minimally invasive radical surgery for pancreatic ductal adenocarcinoma (version 2022)].
;
Zhonghua Wai Ke Za Zhi; 2023 Mar; 61(3):187-195. PubMed ID: 36650963
[TBL] [Abstract][Full Text] [Related]
14. Oncologic outcomes of minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
van Hilst J; Korrel M; de Rooij T; Lof S; Busch OR; Groot Koerkamp B; Kooby DA; van Dieren S; Abu Hilal M; Besselink MG;
Eur J Surg Oncol; 2019 May; 45(5):719-727. PubMed ID: 30579652
[TBL] [Abstract][Full Text] [Related]
15. Impact of Intraoperative Dexamethasone on Surgical and Oncologic Outcomes for Patients with Resected Pancreatic Ductal Adenocarcinoma.
Newhook TE; Soliz JM; Prakash LR; Hancher-Hodges S; Speer BB; Wilks JA; Ikoma N; Kim MP; Lee JE; Katz MHG; Tzeng CD
Ann Surg Oncol; 2021 Mar; 28(3):1563-1569. PubMed ID: 32803553
[TBL] [Abstract][Full Text] [Related]
16. Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-institutional Analysis from the Central Pancreatic Consortium.
Kelly KN; Macedo FI; Seaton M; Wilson G; Hammill C; Martin RC; Maduekwe UN; Kim HJ; Maithel SK; Abbott DE; Ahmad SA; Kooby DA; Merchant NB; Datta J
Ann Surg Oncol; 2022 Sep; 29(9):6004-6012. PubMed ID: 35511392
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Medicaid Expansion on Early-Stage Pancreatic Adenocarcinoma at High- Versus Low-Volume Facilities.
Lima HA; Moazzam Z; Endo Y; Alaimo L; Woldesenbet S; Munir MM; Shaikh C; Resende V; Pawlik TM
Ann Surg Oncol; 2023 Nov; 30(12):7263-7274. PubMed ID: 37368099
[TBL] [Abstract][Full Text] [Related]
18. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
19. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
20. Minimally invasive surgery for stage III colon adenocarcinoma is associated with less delay to initiation of adjuvant systemic therapy and improved survival.
Lee L; Wong-Chong N; Kelly JJ; Nassif GJ; Albert MR; Monson JRT
Surg Endosc; 2019 Feb; 33(2):460-470. PubMed ID: 29967992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
